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A Case of Carcinoid Tumor
Sarah Smith DO, Stanlies D’Souza MD, Toni Chahla MD
Department of Anesthesiology, Baystate Medical Center/Tufts University School of Medicine, Springfield, MA
INTRODUCTION

DISCUSSION

Resection of carcinoid tumors
have significant implications for
anesthetic management due to
concern
for
intraoperative
hemodynamic
changes
of
hypotension or hypertension
and bronchospasm. Octreotide
has now become the mainstay
of therapy for carcinoid tumor
resection. Below we present a
case
of
carcinoid
tumor
resection with the use of
octreotide, in addition to other
agents, to prevent and treat
intraoperative complications.

Carcinoid Tumors
• Occur in only 0.2-10/100,000 people, incidental findings on autopsies
show rates as high as 8%.1
• Develop from neuroendocrine cells and secrete a variety of
neuropeptides and vasoactive substances, including: serotonin,
bradykinin, vasoactive intestinal polypeptide, kallikrein, substance P
and histamine.2
• 75% occur in the GI tract, location of origin correlates with the type of
substance released. Signs and symptoms include flushing, diarrhea,
bronchospasm, hypertension, hypotension and hyperglycemia.3
Intraoperative Management

CASE DESCRIPTION
A 58 year old male with
asymptomatic carcinoid tumor
of the bowel, diagnosed with
positive
octreotide
scan,
presented for resection of the
tumor
from
the
ileocecal
junction. The patient was given
steroids and histamine blockers
prior to induction and an
octreotide infusion was begun.
The patient was induced and
intubated and blood pressure
was monitored perioperatively
with
radial
arterial
line.
Hypotension with systolic blood
pressures less than 80mmHg
occurred
with
tumor
manipulation
and
was
successfully
treated
with
octreotide and phenylephrine.
At the case’s end, the octreotide
infusion was discontinued and
the patient was extubated and
taken to PACU in stable
condition.

Image of patient’s octreotide scan: positive
findings in right lower quadrant

2.4X2.7X3cm carcinoid tumor at the ileocecal
junction seen on IV contrast CT scan

• An arterial line should be placed to monitor significant
hemodynamic changes caused by peptide release. These changes
can be precipitated by anxiety and catecholamine release during
induction. Peptide release can also be precipitated by
hypercapnea, hypotension or hypothermia.3
• To ensure a smooth induction, avoid medications that cause the
release of histamines. Certain non-depolarizing muscle relaxants,
succinylcholine and morphine should be avoided to prevent
precipitation of bronchospasm.
• Avoid beta and alpha adrenergic agonists as these can precipitate
release of peptides.
• Today’s main line of prevention and treatment of symptoms from
peptide release is octreotide, a synthetic somatostatin analog with a
longer half life that prevents hormone release, blocks the actions of
released peptides, and inhibits insulin secretion.1
Perioperatively
• Octreotide can be infused at a rate of 50-100mcg/hr, and boluses of
25-100mcg can be given2 for hypotension, hypertension and
bronchospasm with effects seen in about 10 minutes.
• Circulating peptides can still cause symptoms even after tumor
resection, and octreotide may need to be continued postoperatively.
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CONCLUSION
Octreotide infusion is the mainstay therapy for intraoperative prevention
and management of hemodynamic instability and bronchospasm. Other
agents such as antihistamines and steroids may also be used, while
histamine-releasing agents and adrenergic agonists should be avoided.

